Loading…

Adozelesin, a potent new alkylating agent : cell-killing kinetics and cell-cycle effects

Adozelesin (U-73975) was highly cytotoxic to V79 cells in culture and was more cytotoxic than several clinically active antitumor drugs as determined in a human tumor-cloning assay. Phase-specificity studies showed that cells in the M+early G1 phase were most resistant to adozelesin and those in the...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 1992-09, Vol.30 (5), p.348-354
Main Authors: BHUYAN, B. K, SMITH, K. S, ADAMS, E. G, WALLACE, T. L, VON HOFF, D. D, LI, L. H
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c311t-ead41067ea147b1a608d8a3c565ba16f2e622ed8ad01f7175ca034977ae6cc3a3
cites cdi_FETCH-LOGICAL-c311t-ead41067ea147b1a608d8a3c565ba16f2e622ed8ad01f7175ca034977ae6cc3a3
container_end_page 354
container_issue 5
container_start_page 348
container_title Cancer chemotherapy and pharmacology
container_volume 30
creator BHUYAN, B. K
SMITH, K. S
ADAMS, E. G
WALLACE, T. L
VON HOFF, D. D
LI, L. H
description Adozelesin (U-73975) was highly cytotoxic to V79 cells in culture and was more cytotoxic than several clinically active antitumor drugs as determined in a human tumor-cloning assay. Phase-specificity studies showed that cells in the M+early G1 phase were most resistant to adozelesin and those in the late G1 + early S phase were most sensitive. Adozelesin transiently slowed cell progression through the S phase and then blocked cells in G2. Some cells escaped the G2 block and either divided or commenced a second round of DNA synthesis (without undergoing cytokinesis) to become tetraploid. Adozelesin inhibited DNA synthesis more than it did RNA or protein synthesis. However, the dose needed for inhibition of DNA synthesis was 10-fold that required for inhibition of L1210 cell growth. The observation that cell growth was inhibited at doses that did not cause significant inhibition of DNA synthesis and that cells were ultimately capable of completing two rounds of DNA synthesis in the presence of the drug suggests that adozelesin did not exert its cytotoxicity by significant inhibition of DNA synthesis. It is likely that adozelesin alkylates DNA at specific sites, which leads to transient inhibition of DNA synthesis and subsequent G2 blockade followed by a succession of events (polyploidy and unbalanced growth) that result in cell death.
doi_str_mv 10.1007/BF00689961
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00689961</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1505072</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-ead41067ea147b1a608d8a3c565ba16f2e622ed8ad01f7175ca034977ae6cc3a3</originalsourceid><addsrcrecordid>eNpFkM9Lw0AQhRdRaq1evAt78CRGZ7K_Um-1WBUKXhS8helmUmK3aclGpP71prTY08D7Ph7ME-IS4Q4B3P3jBMBmw6HFI9FHrdIEMq2ORR-U1olxoE_FWYxfAKBRqZ7ooQEDLu2Lz1Gx-uXAsapvJcn1quW6lTX_SAqLTaC2queS5tvwQXoOIVlUIWzDRVVzW_koqS52xG98YMllyb6N5-KkpBD5Yn8H4mPy9D5-SaZvz6_j0TTxCrFNmAqNYB0TajdDspAVGSlvrJkR2jJlm6bcRQVg6dAZT91TQ-eIrfeK1EDc7Hp9s4qx4TJfN9WSmk2OkG_XyQ_rdPLVTl5_z5ZcHNTdHB2_3nOKnkLZUO2r-K8Z7WxmtPoDsNdrpw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Adozelesin, a potent new alkylating agent : cell-killing kinetics and cell-cycle effects</title><source>Springer Nature - Connect here FIRST to enable access</source><creator>BHUYAN, B. K ; SMITH, K. S ; ADAMS, E. G ; WALLACE, T. L ; VON HOFF, D. D ; LI, L. H</creator><creatorcontrib>BHUYAN, B. K ; SMITH, K. S ; ADAMS, E. G ; WALLACE, T. L ; VON HOFF, D. D ; LI, L. H</creatorcontrib><description>Adozelesin (U-73975) was highly cytotoxic to V79 cells in culture and was more cytotoxic than several clinically active antitumor drugs as determined in a human tumor-cloning assay. Phase-specificity studies showed that cells in the M+early G1 phase were most resistant to adozelesin and those in the late G1 + early S phase were most sensitive. Adozelesin transiently slowed cell progression through the S phase and then blocked cells in G2. Some cells escaped the G2 block and either divided or commenced a second round of DNA synthesis (without undergoing cytokinesis) to become tetraploid. Adozelesin inhibited DNA synthesis more than it did RNA or protein synthesis. However, the dose needed for inhibition of DNA synthesis was 10-fold that required for inhibition of L1210 cell growth. The observation that cell growth was inhibited at doses that did not cause significant inhibition of DNA synthesis and that cells were ultimately capable of completing two rounds of DNA synthesis in the presence of the drug suggests that adozelesin did not exert its cytotoxicity by significant inhibition of DNA synthesis. It is likely that adozelesin alkylates DNA at specific sites, which leads to transient inhibition of DNA synthesis and subsequent G2 blockade followed by a succession of events (polyploidy and unbalanced growth) that result in cell death.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/BF00689961</identifier><identifier>PMID: 1505072</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Alkylating Agents - pharmacology ; Animals ; Antineoplastic agents ; Antineoplastic Agents - pharmacology ; Biological and medical sciences ; Cell Cycle - drug effects ; Cell Division - drug effects ; Cell Line - drug effects ; Cell Survival - drug effects ; Cyclohexanecarboxylic Acids - pharmacology ; Cyclohexenes ; DNA - biosynthesis ; Dose-Response Relationship, Drug ; General aspects ; Humans ; Indoles ; Medical sciences ; Pharmacology. Drug treatments ; Protein Biosynthesis ; Time Factors ; Tumor Cells, Cultured - drug effects</subject><ispartof>Cancer chemotherapy and pharmacology, 1992-09, Vol.30 (5), p.348-354</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-ead41067ea147b1a608d8a3c565ba16f2e622ed8ad01f7175ca034977ae6cc3a3</citedby><cites>FETCH-LOGICAL-c311t-ead41067ea147b1a608d8a3c565ba16f2e622ed8ad01f7175ca034977ae6cc3a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=5476854$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1505072$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BHUYAN, B. K</creatorcontrib><creatorcontrib>SMITH, K. S</creatorcontrib><creatorcontrib>ADAMS, E. G</creatorcontrib><creatorcontrib>WALLACE, T. L</creatorcontrib><creatorcontrib>VON HOFF, D. D</creatorcontrib><creatorcontrib>LI, L. H</creatorcontrib><title>Adozelesin, a potent new alkylating agent : cell-killing kinetics and cell-cycle effects</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>Adozelesin (U-73975) was highly cytotoxic to V79 cells in culture and was more cytotoxic than several clinically active antitumor drugs as determined in a human tumor-cloning assay. Phase-specificity studies showed that cells in the M+early G1 phase were most resistant to adozelesin and those in the late G1 + early S phase were most sensitive. Adozelesin transiently slowed cell progression through the S phase and then blocked cells in G2. Some cells escaped the G2 block and either divided or commenced a second round of DNA synthesis (without undergoing cytokinesis) to become tetraploid. Adozelesin inhibited DNA synthesis more than it did RNA or protein synthesis. However, the dose needed for inhibition of DNA synthesis was 10-fold that required for inhibition of L1210 cell growth. The observation that cell growth was inhibited at doses that did not cause significant inhibition of DNA synthesis and that cells were ultimately capable of completing two rounds of DNA synthesis in the presence of the drug suggests that adozelesin did not exert its cytotoxicity by significant inhibition of DNA synthesis. It is likely that adozelesin alkylates DNA at specific sites, which leads to transient inhibition of DNA synthesis and subsequent G2 blockade followed by a succession of events (polyploidy and unbalanced growth) that result in cell death.</description><subject>Alkylating Agents - pharmacology</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Cell Cycle - drug effects</subject><subject>Cell Division - drug effects</subject><subject>Cell Line - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Cyclohexanecarboxylic Acids - pharmacology</subject><subject>Cyclohexenes</subject><subject>DNA - biosynthesis</subject><subject>Dose-Response Relationship, Drug</subject><subject>General aspects</subject><subject>Humans</subject><subject>Indoles</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Biosynthesis</subject><subject>Time Factors</subject><subject>Tumor Cells, Cultured - drug effects</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNpFkM9Lw0AQhRdRaq1evAt78CRGZ7K_Um-1WBUKXhS8helmUmK3aclGpP71prTY08D7Ph7ME-IS4Q4B3P3jBMBmw6HFI9FHrdIEMq2ORR-U1olxoE_FWYxfAKBRqZ7ooQEDLu2Lz1Gx-uXAsapvJcn1quW6lTX_SAqLTaC2queS5tvwQXoOIVlUIWzDRVVzW_koqS52xG98YMllyb6N5-KkpBD5Yn8H4mPy9D5-SaZvz6_j0TTxCrFNmAqNYB0TajdDspAVGSlvrJkR2jJlm6bcRQVg6dAZT91TQ-eIrfeK1EDc7Hp9s4qx4TJfN9WSmk2OkG_XyQ_rdPLVTl5_z5ZcHNTdHB2_3nOKnkLZUO2r-K8Z7WxmtPoDsNdrpw</recordid><startdate>19920901</startdate><enddate>19920901</enddate><creator>BHUYAN, B. K</creator><creator>SMITH, K. S</creator><creator>ADAMS, E. G</creator><creator>WALLACE, T. L</creator><creator>VON HOFF, D. D</creator><creator>LI, L. H</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19920901</creationdate><title>Adozelesin, a potent new alkylating agent : cell-killing kinetics and cell-cycle effects</title><author>BHUYAN, B. K ; SMITH, K. S ; ADAMS, E. G ; WALLACE, T. L ; VON HOFF, D. D ; LI, L. H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-ead41067ea147b1a608d8a3c565ba16f2e622ed8ad01f7175ca034977ae6cc3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Alkylating Agents - pharmacology</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Cell Cycle - drug effects</topic><topic>Cell Division - drug effects</topic><topic>Cell Line - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Cyclohexanecarboxylic Acids - pharmacology</topic><topic>Cyclohexenes</topic><topic>DNA - biosynthesis</topic><topic>Dose-Response Relationship, Drug</topic><topic>General aspects</topic><topic>Humans</topic><topic>Indoles</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Biosynthesis</topic><topic>Time Factors</topic><topic>Tumor Cells, Cultured - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BHUYAN, B. K</creatorcontrib><creatorcontrib>SMITH, K. S</creatorcontrib><creatorcontrib>ADAMS, E. G</creatorcontrib><creatorcontrib>WALLACE, T. L</creatorcontrib><creatorcontrib>VON HOFF, D. D</creatorcontrib><creatorcontrib>LI, L. H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BHUYAN, B. K</au><au>SMITH, K. S</au><au>ADAMS, E. G</au><au>WALLACE, T. L</au><au>VON HOFF, D. D</au><au>LI, L. H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adozelesin, a potent new alkylating agent : cell-killing kinetics and cell-cycle effects</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1992-09-01</date><risdate>1992</risdate><volume>30</volume><issue>5</issue><spage>348</spage><epage>354</epage><pages>348-354</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Adozelesin (U-73975) was highly cytotoxic to V79 cells in culture and was more cytotoxic than several clinically active antitumor drugs as determined in a human tumor-cloning assay. Phase-specificity studies showed that cells in the M+early G1 phase were most resistant to adozelesin and those in the late G1 + early S phase were most sensitive. Adozelesin transiently slowed cell progression through the S phase and then blocked cells in G2. Some cells escaped the G2 block and either divided or commenced a second round of DNA synthesis (without undergoing cytokinesis) to become tetraploid. Adozelesin inhibited DNA synthesis more than it did RNA or protein synthesis. However, the dose needed for inhibition of DNA synthesis was 10-fold that required for inhibition of L1210 cell growth. The observation that cell growth was inhibited at doses that did not cause significant inhibition of DNA synthesis and that cells were ultimately capable of completing two rounds of DNA synthesis in the presence of the drug suggests that adozelesin did not exert its cytotoxicity by significant inhibition of DNA synthesis. It is likely that adozelesin alkylates DNA at specific sites, which leads to transient inhibition of DNA synthesis and subsequent G2 blockade followed by a succession of events (polyploidy and unbalanced growth) that result in cell death.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>1505072</pmid><doi>10.1007/BF00689961</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0344-5704
ispartof Cancer chemotherapy and pharmacology, 1992-09, Vol.30 (5), p.348-354
issn 0344-5704
1432-0843
language eng
recordid cdi_crossref_primary_10_1007_BF00689961
source Springer Nature - Connect here FIRST to enable access
subjects Alkylating Agents - pharmacology
Animals
Antineoplastic agents
Antineoplastic Agents - pharmacology
Biological and medical sciences
Cell Cycle - drug effects
Cell Division - drug effects
Cell Line - drug effects
Cell Survival - drug effects
Cyclohexanecarboxylic Acids - pharmacology
Cyclohexenes
DNA - biosynthesis
Dose-Response Relationship, Drug
General aspects
Humans
Indoles
Medical sciences
Pharmacology. Drug treatments
Protein Biosynthesis
Time Factors
Tumor Cells, Cultured - drug effects
title Adozelesin, a potent new alkylating agent : cell-killing kinetics and cell-cycle effects
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T05%3A28%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adozelesin,%20a%20potent%20new%20alkylating%20agent%20:%20cell-killing%20kinetics%20and%20cell-cycle%20effects&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=BHUYAN,%20B.%20K&rft.date=1992-09-01&rft.volume=30&rft.issue=5&rft.spage=348&rft.epage=354&rft.pages=348-354&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/BF00689961&rft_dat=%3Cpubmed_cross%3E1505072%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c311t-ead41067ea147b1a608d8a3c565ba16f2e622ed8ad01f7175ca034977ae6cc3a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/1505072&rfr_iscdi=true